Summary
The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever done for this disease, it was necessary to develop non- disease-specific clinical assessments, in collaboration with Key Opinion Leaders (KOLs), for use as endpoints. The newness of these tools presented challenges to site selection and training, as well as risks to uniformity in patient recruitment and consistency in data collection.
Register to download
Creating Solutions to Ensure Endpoint Protection in Challenging Rare Disease Trial
You may also be interested in:
Case Study
IIT Program Management Case Study
6+ year relationship with a large biopharma company that needed to change the operating model for their investigator-initiated trials (IIT), in part…
Case Study
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…